Law360, New York (May 17, 2012, 4:01 PM ET) -- Bayer Corp. has agreed to pay $15 million to resolve class action claims that it misled consumers into believing its combination aspirin drugs had received regulatory approval, according to a settlement motion filed in New York federal court Wednesday.
Purchasers of Bayer's enhanced aspirin pills asked the court to sign off on a settlement that will end a multidistrict litigation accusing the drugmaker of selling two separate combination pills that had not been rubber-stamped by the U.S. Food and Drug Administration, saying that the payout represented...
Bayer Pays $15M To Soothe Consumers In Aspirin MDL
To view the full article, take a free trial now.
